Since then, the EMA and UK’s NICE have approved pembrolizumab, both as monotherapy and in combination with chemotherapy, as a first‐line treatment for metastatic or unresectable recurrent HNSCC in patients whose tumours express PD‐L1 with CPS ≥ 1, regardless of the test (antibody and IHC platform) used. Here, CD274 is linked to head and neck squamous cell carcinoma.